NCT01058343已完成1 期
A Phase I-II, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study of Neovacs' IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus.
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Neovacs
- 入组人数
- 28
- 试验地点
- 17
- 主要终点
- Frequency and severity of adverse events
研究概览
简要总结
Interferon alpha (IFNa) is involved in the pathogenesis of systemic lupus erythematosus (SLE)and IFNa levels are associated with the severity of the disease. Blocking IFNa could be an attractive therapeutic strategy. Active immunization with IFNa kinoid (IFN-K) induces a polyclonal antibody response.
This study will evaluate the safety of IFN-K in patients with mild to moderate SLE. It will also measure the induction of anti-IFNa antibodies and evaluate the clinical impact on SLE disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of SLE according to current American College of Rheumatology (ACR) criteria (4 of 11 ACR criteria),
- •SLEDAI ≥4 and ≤10,
- •Positive Anti-nuclear Antibodies (ANA) and/or Positive anti-dsDNA antibodies
- •Male or female between 18 and 50 years of age
- •Current immunity to measles, mumps, rubella and varicella, as evidenced by positive IgG titers at the time of screening,
- •For subjects recruited during local influenza season, current vaccination against seasonal influenza at least 7 days prior to randomization,
- •Vaccination against H1N1 influenza at least 7 days prior to randomization.
- •For subjects with reproductive potential (males and females), use of a reliable means of contraception
- •Written informed consent obtained from the subject.
排除标准
- •Any serious manifestation of lupus at entry, that, in the opinion of the investigator is likely to require initiation of off-protocol medication changes during the course of the study and in particular no BILAG A score,
- •Any non-SLE manifestation likely to require, in the investigator's judgment, treatment with high-dose corticosteroids or the addition of an immunosuppressive regimen during the course of the trial,
- •Received > 20 mg/day of prednisone equivalent for > 7 days during the 30 days prior to screening,
- •Currently receiving or having received pulse dose corticosteroids or intravenous immunoglobulin (IVIg) within 3 months prior to screening,
- •Received cyclophosphamide within 3 months prior to screening,
- •Received a monoclonal antibody during the 6 months prior to screening,
- •Previously received an investigational treatment directed against IFNa,
- •Received B-cell depleting therapy (e.g. Rituximab) within 12 months
- •Received IV antibiotics during the 30 days prior to screening,
- •Significant electrocardiogram (ECG) abnormalities ,
- •Evidence of any clinically significant abnormality on a chest X-ray which, in the opinion of the investigator could represent active infection, latent tuberculosis or treatable manifestation of lupus,
- •Any laboratory abnormality that is clinically relevant
- •History of malignancy except completely excised basal cell carcinoma,
- •Congenital immune deficiency,
- •Positive IgM antibody titers in the presence of negative IgG titers to Epstein-Barr virus (EBV) or cytomegalovirus (CMV),
- •Frequent recurrences of oral or genital herpes simplex lesions (≥ 6 / year),
- •Episode of shingles within one year of screening,
- •Human Immunodeficiency Virus (HIV), hepatitis C virus (HCV) or HBV (HBsAg, anti-HBc ab) positive,
- •Any current signs or symptoms of infection at entry,
- •Administration of any live vaccine within the 3 months prior to study entry
- •Planned use of any investigational or non-registered product
研究组 & 干预措施
IFN-K 3
Experimental
IFN kinoid dose 3
干预措施: IFN-K (Biological)
IFN-K-2
Experimental
IFN kinoid dose 2
干预措施: IFN-K (Biological)
IFN-K 4
Experimental
IFN kinoid dose 4
干预措施: IFN-K (Biological)
IFN-K 1
Experimental
IFN kinoid dose 1
干预措施: IFN-K (Biological)
Saline
Placebo Comparator
saline at same dose as IFN K
干预措施: IFN-K (Biological)
结局指标
主要结局
Frequency and severity of adverse events
时间窗: study duration
次要结局
- Proportion of patients with anti IFNa antibodies(Month 4)
研究者
研究点 (17)
Loading locations...
相似试验
Unknown
2 期
Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney CancerMetastatic Renal Cell CarcinomaNCT01274273University of Aarhus118
已完成
1 期
Omalizumab for LupusSystemic Lupus ErthematosusSjogren's SyndromeNCT01716312National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)17
招募中
不适用
Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLESystemic Lupus Erythematosus of ChildhoodNCT06586710Meyer Children's Hospital IRCCS60
Unknown
不适用
Evaluation of Type I IFN Level and Disease Activity in SLE PatientsElevated Level of IFN Type I in SLE PatientsNCT05446428V.A. Nasonova Research Institute of Rheumatology, Moscow70
已完成
2 期
Low-dose Interleukin-2 for Treatment of Systemic Lupus ErythematosusLupus Erythematosus, SystemicNCT03312335Onur Boyman, MD16